CYPROTEX US LLC

CYPROTEX US LLC specializes in advanced toxicological research and analytical testing services for federal science and environmental agencies, with deep expertise in high-throughput toxicokinetics (HTTK), human neurite outgrowth assays, and network formation studies. The company delivers critical ADME-Tox data using in vitro and computational models to evaluate chemical safety profiles, supporting regulatory decision-making under EPA and DOI mandates. Their technical capabilities encompass quantitative bioanalysis, chemical exposure modeling, and high-content screening assays that bridge pharmacokinetics with neurotoxicological endpoints, enabling predictive risk assessment without reliance on animal testing. This focus on next-generation toxicology methods positions them as a technical partner for agencies transitioning toward non-animal testing paradigms under the Tox21 and ToxCast initiatives. The contractor maintains a strong, sustained relationship with the Department of the Interior and the Environmental Protection Agency, delivering specialized toxicokinetic testing and chemical safety assays that inform environmental risk evaluations and regulatory policy. Their work for HHS supports bioanalytical validation for public health applications, demonstrating adaptability across federal science missions. Operating under NAICS 541715 and 541380, CYPROTEX US LLC is narrowly focused on physical and life sciences R&D and independent laboratory testing, serving the environmental health and chemical safety market with precision. Their niche lies in translating complex biological endpoints into actionable regulatory data using validated, high-throughput platforms. As a small business structured as a 2L entity based in Framingham, Massachusetts, CYPROTEX US LLC operates without federal certifications but maintains a targeted presence in the federal science contracting space, serving mission-critical research needs for agencies committed to modernizing toxicological assessment methodologies.